TY - JOUR
T1 - Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses
T2 - a cross-sectional study
AU - Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)
AU - Shoda, Tetsuo
AU - Wen, Ting
AU - Aceves, Seema S.
AU - Abonia, J. Pablo
AU - Atkins, Dan
AU - Bonis, Peter A.
AU - Caldwell, Julie M.
AU - Capocelli, Kelley E.
AU - Carpenter, Christina L.
AU - Collins, Margaret H.
AU - Dellon, Evan S.
AU - Eby, Michael D.
AU - Gonsalves, Nirmala
AU - Gupta, Sandeep K.
AU - Falk, Gary W.
AU - Hirano, Ikuo
AU - Menard-Katcher, Paul
AU - Kuhl, Jonathan T.
AU - Krischer, Jeffrey P.
AU - Leung, John
AU - Mukkada, Vincent A.
AU - Spergel, Jonathan M.
AU - Trimarchi, Michael P.
AU - Yang, Guang Yu
AU - Zimmermann, Nives
AU - Furuta, Glenn T.
AU - Rothenberg, Marc E.
N1 - Funding Information:
MER is a consultant for PulmOne Therapeutics, Spoon Guru, Celgene, AstraZeneca, GlaxoSmithKline, ClostraBio, Merck, Immune Pharmaceuticals, and NKT Therapeutics; has an equity interest in PulmOne Therapeutics, Spoon Guru, Celgene, and Immune Pharmaceuticals; receives royalties from Teva Pharmaceuticals (for reslizumab); and is an inventor on a patent owned by Cincinnati Children's Hospital Medical Center. TW is co-inventor of a patent on an eosinophilic oesophagitis diagnostic panel issued to the Cincinnati Children's Hospital Medical Center. GWF has received research support from Celgene/Receptos, Regeneron, Shire, and Adare; and has received personal fees from Banner. MHC is a consultant for Shire and Regeneron; and has received research funding from Shire and Regeneron. SKG is a consultant for Abbott, Allakos, QOL, Meritage, and Receptos; and receives research support from Shire. VAM is a consultant for and has received research funding from Shire. NG is a consultant for Allakos. ESD is a consultant for Adare, Alivio, Allakos, Banner, Enumeral, GlaxoSmithKline, Receptos/Celegene, Regeneron, and Shire; has received research funding from Adare, Meritage, Miraca, Nutricia, Receptos/Celgene, and Shire; and has received educational grants from Banner and Holoclara. SSA is a consultant for Regeneron, is an inventor of oral viscous budesonide, patented by UCSD and licensed by Shire; and has research funding from Ferring Research Institute. JMS is a consultant for Regeneron and DBV Technology; and receives research support from the National Institutes of Health, End Allergy Together, Aimmune Therapeutics, FARE, and DBV Technology. GTF is a consultant for Shire; has a patent issued for an oesophageal string test; and receives royalties from UpToDate. IH reports grants and personal fees from Regeneron, Receptos, Shire, and Adare. TS reports a patent pending (Tech ID 2018-0212); and declares research support from the Japan Society for the Promotion of Science KAKENHI grant-in-aid for young scientists and a research fellowship from the Uehara Memorial Foundation, Japan. All other authors declare no competing interests.
Funding Information:
The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR; funded by the National Institutes of Health [NIH], grant U54 AI117804) is part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), and is co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and NCATS. CEGIR is also supported by patient advocacy groups including the American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Disease (CURED), and Eosinophilic Family Coalition (EFC). JPK is supported by the NIH (grant U54TR001263). We thank Amanda Rudman-Spergel for guidance and input; Shawna Hottinger for editorial assistance; and colleagues and clinical support staff in the CEGIR for procuring biopsy specimens and clinical data.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/7
Y1 - 2018/7
N2 - Background: Eosinophilic oesophagitis is understood in terms of quantifiable histological, endoscopic, and molecular features. Data are scant for inter-relations of these features and their potential to identify distinct disease endotypes. We aimed to identify clinical–pathological correlations between endoscopic and histological disease variables by transcription profiling of the oesophagus of patients with eosinophilic oesophagitis of varying severity and disease activity states. Methods: We did a cross-sectional study across ten hospital sites in the USA associated with the Consortium of Eosinophilic Gastrointestinal Disease Researchers. We analysed oesophageal biopsy specimens taken from paediatric and adult patients with eosinophilic oesophagitis (discovery cohort), using the eosinophilic oesophagitis diagnostic panel (EDP), a set of 96 informative transcripts. Histological and endoscopic features were assessed by quantification of oesophageal eosinophils and use of the eosinophilic oesophagitis histology scoring system (HSS) and the eosinophilic oesophagitis endoscopic reference score (EREFS). Associations among the various histological, endoscopic, and molecular features were analysed by Spearman correlation. Results were replicated in a biologically independent, single-centre, validation cohort of patients with active eosinophilic oesophagitis. Findings: The discovery cohort contained 185 samples and the validation cohort comprised 100 specimens. In the discovery cohort, EDP showed intersite consistency, significant correlation with oesophageal eosinophils (p<0·0001), and similar findings between paediatric and adult patients. Of eight HSS domains, basal zone hyperplasia correlated with the EDP (median Spearman ρ 0·47 [IQR 0·36–0·60]). Of five EREFS features, distal furrows correlated with the EDP (median Spearman ρ 0·42 [0·32–0·50]). By analysing active eosinophilic oesophagitis in the discovery cohort, the EDP identified three clusters associated with distinct endotypes (termed EoEe1–3) despite similar eosinophil levels. EoEe1 was associated with a normal-appearing oesophagus (risk ratio [RR] 3·27, 95% CI 1·04–10·27; p=0·0443), an inverse association with a history of oesophageal dilation (0·27, 0·09–0·82; p=0·0105) and showed relatively mild histological, endoscopic, and molecular changes. EoEe2 showed an inflammatory and steroid-refractory phenotype (RR 2·77, 95% CI 1·11–6·95; p=0·0376) and had the highest expression of inflammatory cytokines and steroid-responding genes. EoEe3 was associated with a narrow-calibre oesophagus (RR 7·98, 95% CI 1·84–34·64; p=0·0013) and adult onset (2·22, 1·19–4·12; p=0·0155), and showed the highest degree of endoscopic and histological severity and the lowest expression of epithelial differentiation genes. These endotypes were replicated in the validation cohort by clustering and with an eosinophilic oesophagitis endotype-prediction algorithm. Interpretation: Our new disease classification stratifies patients with eosinophilic oesophagitis into subgroups with potential clinical and therapeutic significance and provides a framework for a precision medicine approach to eosinophilic oesophagitis. Funding: National Institutes of Health.
AB - Background: Eosinophilic oesophagitis is understood in terms of quantifiable histological, endoscopic, and molecular features. Data are scant for inter-relations of these features and their potential to identify distinct disease endotypes. We aimed to identify clinical–pathological correlations between endoscopic and histological disease variables by transcription profiling of the oesophagus of patients with eosinophilic oesophagitis of varying severity and disease activity states. Methods: We did a cross-sectional study across ten hospital sites in the USA associated with the Consortium of Eosinophilic Gastrointestinal Disease Researchers. We analysed oesophageal biopsy specimens taken from paediatric and adult patients with eosinophilic oesophagitis (discovery cohort), using the eosinophilic oesophagitis diagnostic panel (EDP), a set of 96 informative transcripts. Histological and endoscopic features were assessed by quantification of oesophageal eosinophils and use of the eosinophilic oesophagitis histology scoring system (HSS) and the eosinophilic oesophagitis endoscopic reference score (EREFS). Associations among the various histological, endoscopic, and molecular features were analysed by Spearman correlation. Results were replicated in a biologically independent, single-centre, validation cohort of patients with active eosinophilic oesophagitis. Findings: The discovery cohort contained 185 samples and the validation cohort comprised 100 specimens. In the discovery cohort, EDP showed intersite consistency, significant correlation with oesophageal eosinophils (p<0·0001), and similar findings between paediatric and adult patients. Of eight HSS domains, basal zone hyperplasia correlated with the EDP (median Spearman ρ 0·47 [IQR 0·36–0·60]). Of five EREFS features, distal furrows correlated with the EDP (median Spearman ρ 0·42 [0·32–0·50]). By analysing active eosinophilic oesophagitis in the discovery cohort, the EDP identified three clusters associated with distinct endotypes (termed EoEe1–3) despite similar eosinophil levels. EoEe1 was associated with a normal-appearing oesophagus (risk ratio [RR] 3·27, 95% CI 1·04–10·27; p=0·0443), an inverse association with a history of oesophageal dilation (0·27, 0·09–0·82; p=0·0105) and showed relatively mild histological, endoscopic, and molecular changes. EoEe2 showed an inflammatory and steroid-refractory phenotype (RR 2·77, 95% CI 1·11–6·95; p=0·0376) and had the highest expression of inflammatory cytokines and steroid-responding genes. EoEe3 was associated with a narrow-calibre oesophagus (RR 7·98, 95% CI 1·84–34·64; p=0·0013) and adult onset (2·22, 1·19–4·12; p=0·0155), and showed the highest degree of endoscopic and histological severity and the lowest expression of epithelial differentiation genes. These endotypes were replicated in the validation cohort by clustering and with an eosinophilic oesophagitis endotype-prediction algorithm. Interpretation: Our new disease classification stratifies patients with eosinophilic oesophagitis into subgroups with potential clinical and therapeutic significance and provides a framework for a precision medicine approach to eosinophilic oesophagitis. Funding: National Institutes of Health.
UR - http://www.scopus.com/inward/record.url?scp=85046753556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046753556&partnerID=8YFLogxK
U2 - 10.1016/S2468-1253(18)30096-7
DO - 10.1016/S2468-1253(18)30096-7
M3 - Article
C2 - 29730081
AN - SCOPUS:85046753556
SN - 2468-1253
VL - 3
SP - 477
EP - 488
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
IS - 7
ER -